Home・Stock List・Ironwood Pharmaceuticals Inc

Ironwood Pharmaceuticals Inc

Closed

SectorHealthcare

4.25 2.91

Buy Sell

Overview

Share price change

24h

Current

Min

3.89

Max

4.37

Key metrics
By Trading Economics
Income	-21M 41M
Sales	59M 107M
P/E Sector Avg	7.129 68.51
EPS	0.24
Profit margin	38.282
Employees	100
EBITDA	66M 75M

Market Stats
By TradingEconomics
Market Cap	-28M 728M
Previous open	1.34
Previous close	4.25

News Sentiment

By Acuity

22%

78%

58 / 340 Healthcare

Ironwood Pharmaceuticals Inc Chart

Past performance is not a reliable indicator of future results.

Related News

6 Aug 2026, 23:06 UTC

Ironwood Pharmaceuticals shares are higher in after-market hours, reflecting positive movement since Thursday's close. No specific news was identified to explain the price action.

5 Aug 2026, 23:02 UTC

Ironwood Pharmaceuticals shares are higher in after-market trading, continuing a notable increase since Wednesday's close, despite no specific news identified.

4 Aug 2026, 23:01 UTC

Ironwood Pharmaceuticals Inc. shares are lower in after-market trading, showing routine volatility while remaining above the 20-day moving average. No specific news was identified.

3 Aug 2026, 19:26 UTC

Ironwood Pharmaceuticals is trading higher today, continuing a rally since Friday's close, amid broader market gains and falling energy prices.

31 Jul 2026, 23:26 UTC

Ironwood Pharmaceuticals Inc shares are trading higher in after-market hours, maintaining upward momentum since Friday's close. No specific news was identified for this movement.

30 Jul 2026, 20:51 UTC

Ironwood Pharmaceuticals shares declined in after-market trading, despite broader market gains. The stock remains below its 20-day moving average and near a one-month low.

29 Jul 2026, 20:04 UTC

Ironwood Pharmaceuticals Inc shares are trading lower amid broader market dynamics, including rising oil prices due to escalating Middle East tensions.

27 Jul 2026, 20:06 UTC

Ironwood Pharmaceuticals shares are higher today, reflecting broader market dynamics, despite earlier declines and a significant drop in oil prices.

24 Jul 2026, 23:26 UTC

Ironwood Pharmaceuticals shares gained modestly in after-market trading, following a volatile session amid broader turmoil in the bond market.

20 Jul 2026, 18:36 UTC

Ironwood Pharmaceuticals Inc is trading higher, reaching a session peak before settling within its one-month range. No specific news was identified for today's movement.

Peer Comparison

Price change

Ironwood Pharmaceuticals Inc Forecast

Rating Consensus

By TipRanks

Buy

1 ratings

Buy

Hold

Sell

Based on 1 analysts giving stock ratings to Ironwood Pharmaceuticals Inc - Dist in the past 3 months.

Sentiment

By Acuity

58 / 340 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Ironwood Pharmaceuticals Inc

Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; Apraglutide, a next-generation, long-acting synthetic peptide analog of glucagon-like peptide-2, as a differentiated therapeutic for rare diseases, including short bowel syndrome dependent on parenteral support and acute graft versus host disease; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.